India, Oct. 24 -- Global pharmaceutical major Lupin Limited has announced the launch of an authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States.
The medication is indicated for the chronic management of patients with urea cycle disorders (UCDs) who cannot be adequately controlled through dietary protein restriction and/or amino acid supplementation alone.
With this launch, Lupin continues to expand its presence in the U.S. specialty and rare disease market, offering patients a cost-effective treatment alternative for managing urea cycle disorders.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....